GENERAL COMMENTS
The manuscript needs a major improvement.
Major comments: 1) In literature has been reported some cut-points for LMR/NLR in Bcell lymphomas (especially for LMR), so would be more useful validate the proposed thresholds in an external database (evaluate the reproducibility), rather than calculate new cut-points.
2) About the cut-off. The mortality is a time to event data, thus the authors should find the cut-off from a) Cox model (for example AUC according to Heagerty approach) or b) at fixed time of follow-up (for example at 5 or 10 years of followup, excluding from logistic regression patients censored before 5 or 10 years).
3) Did the authors check the functional form (linear, quadratic, logarithmic …) of LMR/NLR with the log(HR) in PFS and OS? 4) Given the small sample size and the small number of events, the reproducibility of the cut-off obtained in this study is questionable. The authors could try to evaluate the stability of the cut-point by means of bootstrap techniques. 5) Did the authors check the interaction between rituximab use and LMR/NLR levels? In other word, LMR/NLR show a homogeneous effect in patients treated with or without rituximab?
Minor comments: 1) Figure 1 . Please, adding the censoring symbol in the KaplanMeier curves.
2) Statistical method. Perhaps the "ranges (minimum, maximum)" are associated at the continuous variables, not at categorical variables. 
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GENERAL COMMENTS
The authors described that high LMR at diagnosis and high NLR at relapse had prognostic impact in patients with FL. I think this conclusion is not reliable because of the following reasons. 1. Treatment regimen is not uniform. If the authors draw any conclusions by using LMR or NLR, the treatment should be uniform in this relatively small cohort analysis. 2. In the article summary, the authors stated " Our study included patients without exposure to rituximab so that our result is also applicable to regions where rituximab is less accessible.". This is incorrect. To prove this, they must analyze in patient cohort treated without rituximab only. This is also applied in RT alone group. 3. The data is not validated in an independent cohort. Reproducibility is needed to establish a new risk factor. The manuscript needs a major improvement.
VERSION 1 -AUTHOR RESPONSE
Major comments:
1) In literature has been reported some cut-points for LMR/NLR in B-cell lymphomas (especially for LMR), so would be more useful validate the proposed thresholds in an external database (evaluate the reproducibility), rather than calculate new cut-points.
Response: We recognise the importance of an external validation set, but we do not have access to independent data. Thus, we have decided, in line with your suggestion, to use cross-validation to evaluate the area under curve (AUC). After fitting the binary logistic regression models, the predictive performance was assessed via the AUC. AUC was estimated for a sample (the test sample) that is independent of the sample used to predict the dependent variable (the training sample) using 10-fold cross-validation. This strategy allows us to generate a more realistic estimate of predictive performance in absence of an external validation set.
We used the Stata user written command cvAUROC which implements k-fold cross-validation for the AUC for a binary outcome after fitting a logistic regression model. We added a new reference in our statistical methods for the cvAUROC Stata command:
"Luque-Fernandez, MA; Maringe, C; Nelson, P; (2017) CVAUROC: Stata module to compute Crossvalidated Area Under the Curve for ROC Analysis after Predictive Modelling for Binary Outcomes. EconPapers."
2) About the cut-off. The mortality is a time to event data, thus the authors should find the cut-off from: a) Cox model (for example AUC according to Heagerty approach) or b) at fixed time of follow-up (for example at 5 or 10 years of follow-up, excluding from logistic regression patients censored before 5 or 10 years).
Response: Thank you for your suggestion. We recognize that accounting for time and censoring is important to evaluate LMR/NLR performance to classify individuals according to their vital status at the end of follow-up. Based on the Shen and Yuan paper, we fitted two weighted binary logistic models including time as covariates. Weights were computed to adjust for the inverse probability of censoring. We also added the reference highlighted below: Response: Yes, we did. In our methods section, we stated that we developed a sensitivity analysis to evaluate the robustness of our findings in the multivariate analysis. We assessed departs from linearity and the function of LMR/NLR. We now have stated it in the methods section.
4) Given the small sample size and the small number of events, the reproducibility of the cut-off obtained in this study is questionable. The authors could try to evaluate the stability of the cut-point by means of bootstrap techniques. Response: Thank you for this insightful comment. Following your suggestion, we used crossvalidation techniques to assess the performance of the cutoff values.
5) Did the authors check the interaction between rituximab use and LMR/NLR levels? In other word, LMR/NLR show a homogeneous effect in patients treated with or without rituximab? Response: Thank you for your comment. Yes, we evaluated the interaction between rituximab and LMR/NLR levels. However, no conclusive evidence can be extrapolated given the reduced sample size for the secondary analysis.
Minor comments: 1) Figure 1 . Please, add the censoring symbol in the Kaplan-Meier curves.
Response: Thank you. We have modified our Kaplan-Meier curves according to your suggestion.
2) Statistical method. Perhaps the "ranges (minimum, maximum)" are associated at the continuous variables, not at categorical variables.
Response: Thank you for pointing this out. We have amended our manuscript according to this comment.
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